Physician profile
Patrick P Litam
NPI 1447203054
$9,759.25
in general payments reported to CMS, 2019-2025
83 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,217 · 2020: $617 · 2021: $280 · 2022: $1,052 · 2023: $1,516 · 2024: $1,803 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,403.00 |
| Education | $190.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,109.25 | 2019-2025 | Tecvayli, Talvey, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $634.01 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Novartis Pharmaceuticals Corporation | $498.52 | 2019-2025 | |
| Pfizer INC. | $498.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $490.40 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Astellas Pharma US INC | $448.14 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Sirtex Medical INC | $372.66 | 2021-2024 | Sir-Spheres Microspheres |
| Genzyme Corporation | $372.37 | 2019-2025 | |
| Celgene Corporation | $365.20 | 2019-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $306.95 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $294.24 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Abbvie INC. | $264.32 | 2019-2025 | |
| Incyte Corporation | $217.19 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Myriad Genetic Laboratories, INC. | $202.05 | 2023-2025 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $200.08 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $198.32 | 2019-2023 | Lumakras |
| Seagen INC. | $189.23 | 2019-2025 | |
| Emd Serono, INC. | $148.92 | 2019-2025 | |
| Genentech USA, INC. | $144.44 | 2019-2025 | Tecentriq, Lunsumio, Polivy |
| Regeneron Healthcare Solutions, INC. | $129.47 | 2019-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $115.90 | 2019-2025 | |
| Sobi, INC | $105.78 | 2023-2025 | |
| Caris Mpi, INC. | $103.11 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $99.77 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.57 | 2019-2025 | Gilotrif |
| Genmab U.S., INC. | $86.66 | 2023-2025 | Tivdak, Epkinly |
| Pharmacosmos Therapeutics INC. | $84.67 | 2024-2025 | Monoferric |
| Blueprint Medicines Corporation | $76.03 | 2022-2025 | Ayvakit |
| Beigene USA, INC. | $75.46 | 2023-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $73.59 | 2023-2025 | Onivyde, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $70.98 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $70.55 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $62.98 | 2024-2025 | Qinlock, Romvimza |
| Secura Bio, INC. | $60.54 | 2020-2025 | Copiktra |
| Apellis Pharmaceuticals, INC. | $57.37 | 2024-2025 | Empaveli |
| Exelixis INC. | $56.62 | 2019-2023 | Cabometyx |
| Eisai INC. | $52.08 | 2024-2025 | |
| Stryker Corporation | $51.50 | 2025 | Optablate |
| Rigel Pharmaceuticals, INC. | $51.00 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Tesaro, INC. | $50.71 | 2019 | |
| Pharmaessentia USA Corporation | $50.35 | 2023-2024 | Besremi |
| Tempus Ai, INC | $49.55 | 2024-2025 | Xt Cdx |
| Kyowa Kirin, INC. | $49.25 | 2023-2025 | Poteligeo |
| Daiichi Sankyo INC. | $48.81 | 2023-2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $48.75 | 2019-2024 | Xarelto |
| Karyopharm Therapeutics INC. | $48.01 | 2020-2024 | Xpovio |
| Agios Pharmaceuticals, INC. | $44.75 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $43.83 | 2023-2025 | Jemperli |
| Adaptive Biotechnologies Corporation | $42.38 | 2024-2025 | Clonoseq |
| Mirati Therapeutics, INC. | $41.05 | 2023-2024 | Krazati |
| Springworks Therapeutics, INC. | $39.40 | 2024-2025 | Ogsiveo, Gomekli |
| Emmaus Medical, INC. | $38.76 | 2023 | Endari |
| Spectrum Pharmaceuticals INC. | $37.88 | 2023-2025 | Rolvedon |
| Helsinn Therapeutics (U.S.), INC. | $35.12 | 2019 | |
| Heron Therapeutics, INC. | $34.38 | 2019-2020 | |
| Dova Pharmaceuticals | $28.82 | 2019-2020 | |
| Coherus Oncology, INC. | $27.32 | 2023 | |
| Beone Medicines USA, INC. | $27.12 | 2025 | Tevimbra |
| Trisalus Life Sciences, INC. | $26.76 | 2025 | Trinav Infusion System |
| Corcept Therapeutics | $25.57 | 2025 | Korlym |
| Legend Biotech USA INC. | $22.91 | 2025 | Carvykti |
| Amneal Pharmaceuticals LLC | $22.72 | 2025 | Alymsys |
| Adc Therapeutics America, INC. | $22.16 | 2024 | |
| Geron Corporation | $21.59 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $21.10 | 2024 | |
| Stemline Therapeutics INC. | $21.09 | 2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $19.85 | 2023 | |
| Servier Pharmaceuticals LLC | $19.67 | 2024 | |
| Progenics Pharmaceuticals, INC. | $19.60 | 2023 | Pylarify |
| Sumitomo Pharma America, INC. | $15.96 | 2024 | Orgovyx |
| Novocure INC. | $15.73 | 2025 | Optune Lua (Novottf-200t) |
| Cti Biopharma Corp. | $15.41 | 2023 | Vonjo |
| Pharmaand Gmbh | $14.80 | 2025 | Rubraca |
| Array Biopharma INC | $14.80 | 2025 | Braftovi |
| Tolmar, INC. | $14.80 | 2025 | Rubraca, Eligard |
| Taiho Oncology, INC. | $14.77 | 2025 | |
| Kite Pharma, INC. | $14.53 | 2025 | Yescarta |
| Novo Nordisk INC | $14.39 | 2023 | Rebinyn, Novoseven, Novoeight |
| Mylan Institutional INC. | $14.02 | 2019 | |
| Puma Biotechnology, INC. | $12.97 | 2019 | |
| Clovis Oncology, INC. | $12.14 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.97 | 2019 | |
| Medtronic USA, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
Myrisk $202Imbruvica $173Opdivo $171Reblozyl $165Keytruda $163Jakafi $157Epkinly $140Sir-Spheres Microspheres $118Talvey $112Tecvayli $112Kisqali $109Enhertu $109Eliquis $108Mi Cancer Seek $103Fruzaqla $102Lynparza $97.46Padcev $96.31Imfinzi $89.55Monoferric $84.67Vonjo $79.24Libtayo $79.17Brukinsa $75.46Onivyde $73.59Jaypirca $71.80Verzenio $71.80Xtandi $70.50Rybrevant $65.96Ibrance $65.71Tivdak $64.91Qinlock $62.98Opdualag $60.80Paxlovid $59.58Carvykti $58.48Orgovyx $57.56Empaveli $57.37Talzenna $55.59Ayvakit $54.85Sarclisa $54.27Pluvicto $53.79Fabhalta $53.67Stivarga $52.71Tecentriq $52.26Lenvima $52.08Optablate $51.50Besremi $50.35Scemblix $50.05Poteligeo $49.25Calquence $45.31Venclexta $45.14Ninlaro $44.94Pyrukynd $44.75Jemperli $43.83Piqray $43.44Monjuvi $43.18Clonoseq $42.38Comirnaty $42.08Doptelet $41.95Alunbrig $41.60Krazati $41.05Tukysa $40.97Erleada $40.79Trodelvy $40.18Copiktra $39.86Tavalisse $38.86Rezlidhia $38.86Endari $38.76Braftovi $38.70Rolvedon $37.88Somatuline Depot $36.50Gilotrif $35.98Lynozyfic $35.69Darzalex $35.57Xarelto $34.81Inlyta $34.79Vitrakvi $33.83Xpovio $33.39Bosulif $32.38Vyloy $31.20Rubraca $29.60Lumakras $28.48Udenyca $27.32Tevimbra $27.12Trinav Infusion System $26.76Lunsumio $25.76Polivy $25.76Niktimvo $25.58Korlym $25.57Tabrecta $24.83Promacta $24.65Tasigna $24.38Mektovi $23.90Retevmo $23.74Alymsys $22.72Altuviiio $22.30Rytelo $21.59Elahere $21.41Hemlibra $21.21Fotivda $21.10Orserdu $21.09Jevtana $20.80
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Litam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.